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Case 
A 35-year-old man with no significant medical history 
presented to a university ED complaining of anxiety. tremors and 
insomnia.  The patient denied use of common street drugs or 
tobacco.  He admitted to social weekend alcohol consumption, 
but had not been drinking during the preceding 2 weeks. His vital 
signs were:  temperature 37.2OC, pi~lse  105/min. respirations 161 
min.  blood pressure  148188 mmHg.  Physical examination re- 
vealed a muscular young man with a resting tremor and obvious 
anxiety. but was otherwise unremarkable. The patient's girlfriend 
took the physician aside and revealed the actual reason for seeking 
ED  treatment was that he was trying to quit using GHB. She also 
confirmed he had nor been drinking alcohol and was not a habitual 
alcohol user. The patient subsequently admitted to using increas- 
ing amounts of GHB for the previous 2.5 years, and was consum- 
ing 1 to 2 "capfuls" of liquid GHB 4 to 6 times daily (exact dose 
unknown). His last dose was 20 hours prior to presentation. The 
patient first started using  GHB at the urging of  weight-lifting 
friends.  He had attempted to quit multiple times without suc- 
cess.  A presumptive diagnosis of GHB withdrawal was made. 
The patient was treated with 20 mg of oral diazepam in the ED, 
which relieved the tremors. After a 3-hour observation period. he 
was discharged with a 3-day prescription for lorazepam. referred 
to a local primary care clinic and given substance abuse counseling 
information. 
Although laboratory confirmation of GHB use was not 
obtained.  this case illustrates the features of GHB withdrawel 
that will be discussed in this article: the clinical manifestations of 
the GHB withdrawal syndrome, the similarities to withdrawal 
from other sedative-hypnotic agents. and the treatment options. 
Recognizing and treating GHB withdrawal will be of increasing 
importance to emergency physicians as its popularity continues 
to grow. 
Clirlical Marl(festc~tions 
GHB is a naturally occurring substance. found in high- 
est concentrations in the basal ganglia and hypothalamus of brain 
tissue.' Although commercial sale of GHB is illegal in the United 
States. it is still easy to obtain, as evidenced by its abundance at 
rave parties.  GHB recipes and various precursor formulations 
containing gamma-butyrolactone, 1.4-butanediol, dihydro-2(3H)- 
furanone and 4-butanolide are also available via the internet.? The 
precursors are converted in vivo to GHB after ingestion.  GHB is 
popular among rave crowds and body-builders. and has been im- 
plicated as a "date-rape"  drug.  Investigational narcolepsy treat- 
ment is the only FDA approved use for GHB in the United States. 
As GHB use has increased because of its sedative. eu- 
page 16 
phoric and purported anabolic effects, a clinical GHB withdrawal 
syndrome has emerged among habitual users.  The habit-forming 
nature of GHB and a description of clinical features associated 
with abruptly stopping or decreasing use was first noted in 1994.' 
A withdrawal syndrome is characterized by  various expectant 
psychological andlor physical signs and symptoms caused by the 
abrupt cessation of  a drug that is used habitually.  Given the 
~nultiple  independent descriptions of similar signs and symptoms 
associated with the cessation of chronic GUB use. GUB is now 
considered to possess a true withdrawal syndrome.""  Based on 
these case series and reports, the signs and symptoms of GHB 
withdrawal include varying degrees of anxiety. agitation. and in- 
somnia.  Ophthalrnoplegia with  sixth cranial  nerve palsies  has 
been reported in association with GHB withdrawal, although this 
niay represent concomitant thiamine deficiency.  Autonomic hy- 
peractivity manifesting as diaphoresis,  tremors.  tachycardia or 
elevated blood pressure is commonly reported.  Behavioral and 
psychiatric features include paranoia, hallucinations (auditory and/ 
or visual) and delirium.  Syn~ptoms  may manifest as soon as 12 
hours after last use and may last LIP  to 12 days.  It is believed that 
more severe symptoms occur in individuals with longer habits and 
in those taking larger amounts of CHB. Many patients will also 
have a history of prior GHB cessation  failure^.^ 
The largest report of cases implicating a physical de- 
pendence to GHB came from Italian researchers using GHB for 
treatment of alcohol dependence.'  Eleven patients (10%  of sub- 
jects completing a 24 week protocol of t.i.d. dosing of 50rngIkg 
CHB)  developed "cravings"  for the drug and voluntarily increased 
their doses to achieve ailxiolytic and hypnotic effects.  The au- 
thors noted that anxiety and insomnia were reported after decreas- 
ing the GHB doses. which  likely represented mild GHB with- 
drawal. 
Sii?zilarih to Ofher  Withcirawal Syflch-ortles 
GHB withdrawal appears to be very similar to ethanol, 
benzodiazepine (BZD) and barbiturate withdrawal. This similar- 
ity is likely related to GHB's chemical structural similarity with 
GABA. the principle  inhibitory  CNS neurotransmitter.  GHE 
exhibits a marked affinity for the GABA,  receptor. compared to 
the GABA, receptor, as well as an affinity for a recently discov- 
ered CHB-specific receptor.  An extensive review of the neurop- 
harmacology of GHB by TunnicliH  reveals that low doses of 
CHB tend to inhibit CNS  dopamine release, whereas in higher and 
sustained doses. analogous to a habitual user, CNS dopamine lev- 
els increase. A decrease or total cessation of the dependent drug is 
all that is needed to precipitate the clinical withdrawal, a feature 
common to many sedative-hypnotic agents. 
Table  1 shows the time course of  symptoms for the 
withdrawal syndromes from GHB and some other substances of 
abuse.  Autoi~omic  hyperactivity is common in CNS depressant 
withdrawals, with symptoms ranging from mild tachycardia and 
tremor to extreme diaphoresis and elevated blood pressure.  Sei- 
zures have not been reported to occur in GHB withdrawal, how- 
ever, the number of case reports is relatively small.  Aside froin 
seizures, no other clinical feature reliably distinguishes GHB with- 
drawal froin the other sedative-hypnotic withdrawal syndromes. 
Thus, obtaining a truthful history from the patient, a close friend 
or relatives is crucial. 
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the diagnosis is straightforward.  However, for patients with the 
myriad of symptoms which by themselves are not diagnostic or 
pathognomonic, making the diagnosis and initiating treatment can 
be challenging.  Negative urine or serum toxicology screens for 
other comrnon drugs of abuse can be useful in making the diagno- 
sis.  GMB, however, is not detected by routine drug tests.  Spe- 
cific serum or urine testing for GHB is not generally indicated and 
is not widely available. except at regional specialty labs.  There 
.!ppears  to be cross-reactivity of GHB with ethanol, BZDs and 
opiates, which may explain why  many  patients coingest these 
other substances, perhaps in an attempt to offset the withdrawal 
symptoms."-""  GWB  has been used  successfully  for over a 
decade in Europe to treat  opioid and alcohol dependence."" 
lending fitsther support to the notion of pharmacological cross- 
tolerance among these CNS depressants. 
Treutmeltr Options 
Clinically. patients respond well to BZD treatment and 
supportive measures while other diagnoses are worked up and 
excluded. Table 2 summarizes the various medications that have 
been reported as useful for GHB withdrawal.  Case reports indi- 
cate that the best results are achieved using a benzodiazepine, 
alone or in combirtation with an antipsychotic agent. Inter~nedi- 
ate- to long-acting BZDs are emerging as the first-line treatment 
of choice: 20mg oral diazepam or 4mg oral lorazepam is a sug- 
gested starting  dose.  Massive amounts of  sedatives (507mg 
lorazepam and  120mg diazepam in one patient over 90h) have 
been reported in one case series9  Behavioral and psychotic 
features of GHB withdrawal respond to antipsychotic medica- 
tions.  Referral to outpatient substance abuse and support groups 
is recommended.  Patients with severe withdrawal features, he- 
modynamic instability, florid psychosis or those requiring large 
doses of medication to control symptoms should be admitted to 
an appropriate monitored unit for continuous cardiopulmonary 
and neurologic monitoring. 
TABLE I 
Gonznzorz  U7it/zdr-avt~al  Syndromes 
De~endenl  Substance  Onset of Symptoms 
Duration 
GEB  12  h-12 days 
1-7 days 
Sedative-hypnotics  2-7 days 
1-2 weeks 
(BZD, Barbiturates) 
Ethanol  6-24 h 
2-5 days 
0  pioids  4-36 h 
3-14 days 
Sumnzary 
Habitual ingestion of GHB has been associated with 
a withdrawal  syndrome consisting of autonomic hyperac- 
tivity and various behavioral and psychotic features when 
the drug is stopped or the dose is decreased.  The descrip- 
tion of a GHB withdrawal syndrome is based on multiple, 
independent descriptions of similar clinical presentations in 
patients with admitted or confirmed GHB habitual use.  GHB 
withdrawal is similar to other sedative-hypnotic withdrawal 
syndromes. The popularity of CHB with the rave crowd and 
body-builders is increasing. Emergency physicians need to 
be aware of the signs and symptoms associated both with 
GHB intoxication and with GHB withdrawal.  Benzodiaz- 
epines are first-line treatment for mild GHB withdrawal; se- 
vere cases with unstable vital signs or florid psychosis should 
be treated in an inpatient setting. 
TABLE 2 
Medications Used in GHB Withdrawal 
Benzodiazepines 
lorazepam "6.7.9 
diazepam 8.9.1 
Antipsychotics 
haldoperidol 6.7 
chlorpromazine 
Phenobarbital 
(reference 15 also used unspecified BZDs and 
antipsychotics) 
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Emerging infections continues to be a hot topic in the infectious 
disease literature.  Articles continue to be published  revealing 
more insights ink) new diseases and disease processes.  PCR and 
niolecular rech~iiques  have made this detective work much reli- 
zbie and accurate.  Some of the moye recent articles include the 
following: 
Transmission of Lyme disease.  How long nwst a tick bike? 
Ticks can remain attached  to humans for long periods of time 
feeding on blood. It has been debated hcw long a tick must remain 
attached for the Lyme spirochete Borrelia  bzirgdo~feri  to actu- 
aliy migrate through the tick and flow into the huinan host.  In 
this study. (IJigt?er,  d!D  2001.  183:773-8). infected  ticks were 
ailowed to attach to mice and Lvere removed at 24 hour intervals 
up to 96 hours.  Infectikity of both ticks and mice for Borreliu 
b~irgdo$er-i  was tested using PCR techniques.  No mice became 
infected if ticks were removed before 24 hours. Between 24 and 
48 i~ours  only 8% of mice became infected. Ticks allowed to feed 
72 hours transmitted Lyme disease to 66% of host mice.  Ticks 
allowed to feed 96  hours transmitted disease to 92% of host mice. 
If this can be correlated to humans. it would nleail that the chances 
of acquiring Lyme disease for a tick [hat had been attached for less 
than 48 hours would be minimal 
Wbai are the con~plications  associated with La Crssse En- 
cepha#i$is"ta  Crosse Encephalitis is one ofthe more virulent 
forms of  California Eircephalitis, a D~iizyi~,ii-,is  wide-spread 
througlaout the United States.  The disease hrs ac animal reser- 
voir an6 is transmitted  to humans via !?osijultoes  primarily  ir! 
rr:rai  areas.  Some states have ngressive mosquito abatement 
control. in part for the control of potentiai!y  serious diseases like 
La Crosse Encephalitis.  1Many children may present with only 
flu-like symptoms such as headache, fever. and discharge from an 
emergency room with a diagnosis of "viral syndmme." However, 
a recent article by McJunkin suggests that some children  cvho 
develop La Crosse Encephalitis may not fair so itre!!  (McJili?kin, 
N  Engl d Med, 314jll]:KOI-7).  In an afiakysis of 127 patients. 
most were found to present with symptoms of headache, fever, 
vomiting. seizures. and disorientation during the summer months. 
Ten percent of children developed a complicated course includirlg 
intubation and ICU care.  Although all children survived, 12% 
overall had significant permanem neuro!ogic problems including 
decreased IQ. paralysis, memory loss and behavioral changes or 
cerebral dysfunction 